相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of olaparib in the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis
Yan Wang et al.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (2022)
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Osnat Elyashiv et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
Anita Mansouri et al.
BMJ OPEN (2021)
Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis
Wenlin Chen et al.
FRONTIERS IN ONCOLOGY (2021)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
J. A. Ledermann et al.
ESMO OPEN (2021)
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
Angeles Alvarez Secord et al.
GYNECOLOGIC ONCOLOGY (2021)
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
Joyce F. Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells
Majid Momeny et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
J. F. Liu et al.
ANNALS OF ONCOLOGY (2019)
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Alanna R. Kaplan et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Mansoor Raza Mirza et al.
LANCET ONCOLOGY (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models
Hyoung Kim et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Cediranib
Weifeng Tang et al.
CLINICAL PHARMACOKINETICS (2017)
Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer
Jianguo Li et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
Juan W. Valle et al.
LANCET ONCOLOGY (2015)
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
R. Paul Symonds et al.
LANCET ONCOLOGY (2015)
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
S. A. Laurie et al.
EUROPEAN JOURNAL OF CANCER (2014)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu et al.
LANCET ONCOLOGY (2014)
Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies
Jane Kendrew et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Targeting tyrosine-kinases in ovarian cancer
Matteo Morotti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
David M. Hyams et al.
INVESTIGATIONAL NEW DRUGS (2013)
A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer North Central Cancer Treatment Group Study N0528
Grace K. Dy et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study
T. Kato et al.
ANNALS OF ONCOLOGY (2012)
Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
Peter Mulders et al.
EUROPEAN JOURNAL OF CANCER (2012)
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
Paulo M. Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
Hans-Joachim Schmoll et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
Sandra R. Brave et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
AZD2171:: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
SR Wedge et al.
CANCER RESEARCH (2005)
分享论文
